Tag: Biocon Biologics

INTERNATIONAL / NATIONAL & KARNATAKA: GLOBAL HEALTH & PHARMAEUTICALS: Biocon Chief Kiran Mazumdar-Shaw Appointed Member of Court of Regents at Royal College of Surgeons of Edinburgh

Biocon Ltd and Biocon Biologics Ltd Executive Chairperson Kiran Mazumdar-Shaw has been appointed as Regent of the Royal College of Surgeons of Edinburgh (RCSed), a Biocon release said on Thursday.

On her appointment as the latest member to the College’s Court of Regents, Mazumdar-Shaw said: “I am humbled and deeply honoured to be appointed Regent of the Royal College of Surgeons Edinburgh. As the oldest surgical college in the world with just under 30,000 members in 100 countries, the RCSed has been championing the highest standards of surgical and dental practice by providing high quality medical education. I look forward to contributing to the College’s mission and advancing the frontiers of surgical excellence.”

The Court of Regents comprises a group of distinguished and accomplished individuals in their field who provide the college with advice and expertise.

The Royal College of Surgeons of Edinburgh is a prestigious Scottish medical association which was founded in 1505 by Royal Charter granted from King James IV. It is the oldest surgical colleges in the world with nearly 30,000 members in 100 countries, and about half of them are from overseas, touching every stage of the career path from medical students to consultants.

source/content: daijiworld.com (headline edited)

NATIONAL: KARNATAKA: HEALTH & PHARMACEUTICALS: Biocon Biologics’ HULIO, a Humira biosimilar now available in US for Rheumatoid Arthritis Patients

The company also offers a robust patient support programme — HULIO360, providing benefits like verification and prior authorisation support, copay assistance, a bridge programme for eligible patients.

Biocon Biologics Ltd has announced that HULIO (adalimumab-fkjp) injection, a biosimilar for Humira (adalimumab) — used to treat rheumatoid arthritis — is now available for patients in the US, after five years of experience in Europe and two years in Canada.

HULIO meets the rigorous biosimilar approval standards of the FDA. Like Humira, HULIO is citrate-free and is made without natural rubber latex (to help reduce hypersensitivity reactions). The company also offers a robust patient support programme — HULIO360, providing benefits like verification and prior authorisation support, copay assistance, a bridge programme for eligible patients, and at-home nurse injection training.

“The launch of HULIO, our biosimilar adalimumab, is an important milestone as it expands our well-known biosimilar product offering to patients in the United States. This launch builds on our strong presence in oncology and diabetes and reaffirms our commitment to enabling affordable access to biologics,” said Shreehas Tambe, CEO and MD, Biocon Biologics Ltd.  

“We are pleased to make HULIO, a patient-friendly, two-click, pre-filled pen available in the US for patients with certain inflammatory diseases,” said Mathew Erick, Chief Commercial Officer of Advanced Markets, Biocon Biologics Ltd.

source/content: newindianexpress.com (headline edited)